140 million obese Americans x $15,000/year for obesity drugs = . . . uh oh, that can't be right. https://astralcodexten.substack.com/p/semaglutidonomics Semaglutide started off as a diabetes medication. Pharma company Novo Nordisk developed it in the early 2010s, and the FDA approved it under the brand names Ozempic® (for the injectable) and Rybelsus® (for the pill). I think “Ozempic” sounds like one of those unsinkable ocean liners, and “Rybelsus” sounds like a benevolent mythological blacksmith. Patients reported significant weight loss as a side effect. Semaglutide was a GLP-1 agonist, a type of drug that has good theoretical reasons to affect weight, so Novo Nordisk studied this and found that yes, it definitely caused people to lose a lot of weight. More weight than any safe drug had ever caused people to lose before. In 2021, the FDA approved semaglutide for weight loss under the brand name Wegovy®. “Wegovy” sounds like either a cooperative governance platform, or some kind of obscure medieval sin. Weight loss pills have a bad reputation. But Wegovy is a big step up. It doesn't work for everybody. But it works for 66-84% of people, depending on your threshold. (Source) Of six major weight loss drugs, only two - Wegovy and Qsymia - have a better than 50-50 chance of helping you lose 10% of your weight. Qsymia works partly by making food taste terrible; it can also cause cognitive issues. Wegovy feels more natural; patients just feel full and satisfied after they've eaten a healthy amount of food. You can read the gushing anecdotes here (plus some extra anecdotes in the comments). Wegovy patients also lose more weight on average than Qsymia patients - 15% compared to 10%. It's just a really impressive drug. Until now, doctors didn't really use medication to treat obesity; the drugs either didn't work or had too many side effects. They recommended either diet and exercise (for easier cases) or bariatric surgery (for harder ones). Semaglutide marks the start of a new generation of weight loss drugs that are more clearly worthwhile. Modeling Semaglutide Accessibility 40% of Americans are obese - that's 140 million people. Most of them would prefer to be less obese. Suppose that a quarter of them want semaglutide. That's 35 million prescriptions. Semaglutide costs about $15,000 per year, multiply it out, that's about $500 billion. Americans currently spend $300 billion per year total on prescription drugs. So if a quarter of the obese population got semaglutide, that would cost almost twice as much as all other drug spending combined. It would probably bankrupt half the health care industry. So . . . most people who want semaglutide won't get it? Unclear. America's current policy for controlling medical costs is to buy random things at random prices, then send all the bills to an illiterate reindeer-herder named Yagmuk, who burns them for warmth. Anything could happen! Right now, only about 50,000 Americans take semaglutide for obesity. I'm basing this off this report claiming “20,000 weekly US prescriptions” of Wegovy; since it's taken once per week, maybe this means there are 20,000 users? Or maybe each prescription contains enough Wegovy to last a month and there are 80,000 users? I'm not sure, but it's somewhere in the mid five digits, which I'm rounding to 50,000. That's only 0.1% of the potential 35 million. The next few sections of this post are about why so few people are on semaglutide, and whether we should expect that to change. I'll start by going over my model of what determines semaglutide use, then look at a Morgan Stanley projection of what will happen over the next decade. Step 1: Awareness I model semaglutide use as interest * awareness * prescription accessibility * affordability. I already randomly guessed interest at 25%, so the next step is awareness. How many people are aware of semaglutide? The answer is: a lot more now than when I first started writing this article! Novo Nordisk's Wegovy Gets Surprise Endorsement From Elon Musk, says the headline. And here's Google Trends:
It's in the News.. the top diabetes stories of the past seven days. This week, the first drug to prevent T1D for any length of time is approved, Eli Lilly takes a financial hit from a Twitter impersonation stunt, Medtronic's 7-day pump infusion set is ready for consumers, Dexcom's G7 gets great reviews from older folks and educators for ease of use, a new study about light at night and diabetes and more! Learn more about the T1D Exchange: www.t1dexchange.com/stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX And by my new book “Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes” available on Amazon in paperback and for kindle. XX Our top story this week, the US U.S. Food and Drug Administration approves teplizumab, the first drug to delay the onset of type 1 diabets. We've been following this for a long time and I'll ink up our previous interviews with Provention Bio, the company that makes it. The brand name will be Tzield (teplizumab-mzwv) and it's an injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes. Tzield is administered by intravenous infusion once daily for 14 consecutive days. Lots of questions here and we'll follow up with an interview and more as soon as I can. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes https://diabetes-connections.com/delaying-a-t1d-diagnosis-the-fda-considers-teplizumab/ XX Our top story this week – the kerfuffle over on Twitter where a couple of accounts spoofed Ely Lilly. The insulin makers stock tanked 6% over just one day late last week, wiping billions of dollars from its market cap. On Nov.10, someone pretending to be Lilly's corporate account tweeted: “We are excited to announced insulin is free now.” You may know that Twitter under new owner Elon Musk was verifying any account with any name for just 8-dollars. Another verified but fake Lilly account tweeted profanities and taunted people who use insulin with higher pricing, again, also fake. Other major insulin makers Sanofi and Novo Nordisk were also caught up in the crossfire, with their stock prices dipping and questions over the high cost of insulin back in the headlines. In the understatement of the year, Lilly CEO David Ricks said – quote – “it probably highlights that we have more work to do to bring down the cost of insulin for more people” XX Mice with diabetes appeared cured after transplantation of insulin-secreting pancreatic islet cells, according to a Stanford Medicine study. The animals' immune systems were coaxed to accept the donated cells prior to transplantation through a three-pronged process that could be easily replicated in humans, the researchers said. No immune-suppressing treatments were necessary after the transplant to prevent rejection of the foreign islet cells. The technique, which builds on earlier work at Stanford Medicine, may open the door to a new type of organ transplant that doesn't require an immunologically matched donor or years on immune-suppressing medication. The difference here is that they do two transplants.. first doing a partial blood stem cell transplant which makes the new pancreas cells recognized as the body's own and less likely to be rejected. Long way to go here, but promising idea. https://med.stanford.edu/news/all-news/2022/11/islet-transplant-diabetes.html XX The first and only 7-day infusion set is ready to go.. after approval more than a year ago – in September of 2021, Medtronic says customers can now order the Medtronic Extended for the 600 and 700 series pumps. In clinical studies of the Medtronic Extended infusion set, study participants observed a decrease in the number of times an infusion set needed to be changed by 50% and the number of infusion set failures associated with high glucose levels was lowered.3,4 Study participants using the Medtronic Extended infusion set commented on the new infusion set being more comfortable to wear compared to their previous infusion sets and were happy with the longer wear feature in helping reduce the overall burden of insulin pump therapy.3,4 Additionally, use of the Medtronic Extended infusion set is estimated to result in annual costs savings of insulin of up to 25% due to a reduced number of infusion set and reservoir changes that result in unrecoverable insulin, as well as plastic waste reduction of up to 50%. https://www.prnewswire.com/news-releases/medtronic-launches-worlds-first-and-only-infusion-set-for-insulin-pumps-that-doubles-wear-time-up-to-7-days-in-us-301677790.html XX Recall for omnipod. This is an issue with the Omnipod 5 Controller charging port and cable. This does not impact the Omnipod 5 Pod, the Omnipod® DASH Insulin Management System, the Omnipod® Insulin Management System, or compatible Android smartphone devices that have the Omnipod 5 App installed. No serious injuries have been reported, but insulet has received reports tht the omnipod 5 controller chargting port or cable is discoloring or even melting due to excess heat. Customers are instructed to called insulet or login to an fda site. I'll link up all of that info in the show notes. at 1-800-6). Additional informati41-2049, which is available 24 hours a day, 7 days a week. Alternatively, Omnipod 5 users can utilize the FDA's MedWatch Adverse Event Reporting program either online (www.fda.gov/medwatch/report.htmExternal Link Disclaimer), by regular mail, or by fax (1-800-FDA-0178on, including instructions to customers to mitigate risk, can be found on the Company's website at www.omnipod.com/insulet-alertsExternal Link Disclaimer. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/insulet-issues-nationwide-voluntary-medical-device-correction-omnipodr-5-controller XX Small study shows that using the Dexcom G7 is easier for older adults to insert and use. Results indicate that G7 CGM system required half as many steps to set up and deploy as the G6 system, with the system's system usability scale survey scores indicating excellent usability. The current study was launched to better understand ease of use and task burden of uptake of Dexcom's G7 CGM system. To do so, investigators designed their study as a formal task analysis with the intent of identifying the number and complexity of tasks associated with deployment of the G7 CGM system compared to the fifth- and sixth-generation systems in adults aged 65 years or older. A cohort of 10 older adults with no prior CGM experience and 10 CDCESs were recruited for inclusion in the investigators' formal task analysis. This analysis assessed ease of use among CDCESs through a survey after hands-on insertion and initiation of the system. For older adults in the study, ease of use was assessed using system usability scale (SUS) survey scores. In the post-test survey and SUS survey given to older adults, no responses lower than neutral were recorded and the SUS score for setup and insertion of the G7 system was 92.8, which investigators noted was reflective of an excellent usability rating. https://www.endocrinologynetwork.com/view/study-finds-dexcom-g7-set-up-is-easier-requires-fewer-tasks-for-older-adults-than-previous-generations XX Control IQ for people with type 2 works well and is safe. New study from Tandem Diabetes Care shows people with type 2 spent 3.6 hours a day long in target range after switching to the tslim x2 pump / Dexcom system from multiple daily injections or basal insulin only https://www.medtechdive.com/news/tandem-pump-dexcom-CGM-Type-2-diabetes/636448/ XX New program from Walgreens to help give more people access to information and diabetes services. Walgreens is teaming up with its Health Corners and third-party clinics to offer free A1C and blood glucose testing and diabetes education during November, Diabetes Awareness Month. For participating locations, visit Walgreens.com/FreeDiabetesScreening and I'll link that up. Walgreen is the largest provider of continuous glucose monitors including the Dexcom G6 and FreeStyle Libre 2 which track glucose levels all day and night – fewer finger sticks required. 7. Affordable care options and tools including Walgreens Prescription Savings Club and Find Rx Coverage which offer insulin savings programs and affordable, predictable copayments on select insulins. Walgreens Find Care provides access to in-person and virtual healthcare expertise from the comfort of one's home. XX Sleeping in a room exposed to outdoor artificial light at night may increase the risk of developing diabetes, according to a huge study of nearly 100,000 Chinese adults. People who lived in areas of China with high light pollution at night were about 28% more likely to develop diabetes than people who lived in the least polluted areas. We told you about a study published earlier this year that showed Sleeping for only one night with a dim light, such as a TV set with the sound off, raised the blood sugar and heart rate of the young people during the sleep lab experiment. These researchers caution that any direct link between diabetes and nighttime light pollution is still unclear, however, because living in an urban area is itself a known contributor to the development of diabetes https://www.cnn.com/2022/11/14/health/night-light-pollution-diabetes-sleep-wellness/index.html XX Researchers are recruiting 20,000 children for a trial to try to identify those at high risk of developing type 1 diabetes. If left undiagnosed or untreated, the condition can lead to life-threatening complications. The trial, led by the University of Birmingham, could mean access to new treatments for children at high risk. The researchers say it may also offer insights that could make screening for type 1 diabetes a possibility. ADVERTISEMENT Type 1 diabetes is an autoimmune condition where the immune system attacks and destroys cells in the pancreas which produce insulin. Insulin is crucial because it moves energy from food from the blood to the cells of the body - without it, the body cannot function properly. Approximately 29,000 children in the UK currently have type 1 diabetes, out of a total of about 400,000 people. For them, managing the condition involves injecting insulin and testing blood glucose levels regularly. The condition is very different to type 2 diabetes, which is often linked to poor diet or an unhealthy lifestyle. The organisers want children aged three to 13 to sign up for the trial, which will analyse their blood - through finger prick and vein tests - for autoantibodies. These are linked to the development of type 1 diabetes. Those with two or more autoantibodies have an 85% chance of having the condition within 15 years, and are almost certain to develop it in their lifetime. 'A simple test could have saved my son' Parth Narendran, professor of diabetes medicine, and Dr Lauren Quinn, clinical research fellow at the University of Birmingham, said there was a need to explore if screening children for type 1 diabetes in the UK would be possible in the UK. "Screening children can reduce their risk of DKA (diabetic ketoacidosis) at diagnosis around fivefold and can help them and their families settle into the type 1 diagnosis better," they said. DKA is a life-threatening complication of type 1 which can occur when diagnosis does not happen quickly. Rachel Connor, director of research partnerships at JDRF UK, which is co-funding the study, said new drugs that target the immune system were progressing through trials. "We are demonstrating that it is possible to delay the need for intensive insulin treatment in those most at risk. When these drugs become available in the UK, we need to be ready to use them straight away," she said. Dr Elizabeth Robertson, from Diabetes UK, which also funded the study, said: "Extra years without the condition means a childhood no longer lived on a knife-edge of blood sugar checks and insulin injections, free from the relentlessness and emotional burden of type 1 diabetes." https://www.bbc.com/news/health-63622084 XX New study on pancreas transplants. These researchers say Up to 90% of people who received a pancreas transplant enjoy freedom from insulin therapy and the need for close glucose monitoring. Biggest drawback is having to take immunosuppressants for the rest of their life. The number of pancreas transplants has declined in recent years. New paper this week in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. Another downside is that this isn't a long-term cure.. the paper says the median graft survival is around eight years and the transplanted pancreas does not always work well, so the patient might not be completely insulin-free. However, I do believe that the combined kidney/pancreas transplant should be considered for all patients with type 1 diabetes with an indication for a kidney transplant.” https://www.healthline.com/health-news/type-1-diabetes-the-benefits-and-limitations-of-a-pancreas-transplant XX Medtrnoic sending emails out regarding the CareLink™ Software outages. . For most of our customers, we were able to resolve the issue relatively quickly through an application fix that took effect when individuals logged out and then logged back into their CareLink™ accounts (reminder of these recommended actions available here). But we know this was not the experience for all, and for some of you the experience was extremely frustrating and lasted longer. Medtnoic is still working to resolve the issue for some customers. They stress this was not because of a security breach but don't give further details. https://app.medtronicdib.mdtpatient.com/e/es?s=357929245&e=822474&elqTrackId=b0ce7494b5bd47ad9b9c672c71086a1c&elq=3155b86a3ca045f0a2e27c182f392387&elqaid=7514&elqat=1&fbclid=IwAR1XYIdfEFpkUrdk-yTk6WKSvlsdncJBNrSy_OpdeuJhHXD2zi78WnxaSG8 XX Women with polycystic ovary syndrome (PCOS) were found to be at higher risk for developing type 2 diabetes over a 30-year period, according to new research presented at the 2022 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo, and described in an article at Healio. PCOS is a hormonal disorder that causes enlarged ovaries containing small fluid-filled sacs, and it can have painful symptoms. Hormonal changes related to PCOS can also have effects throughout the body — including effects related to diabetes. One study estimated that nearly one in five adolescent girls with type 2 diabetes also has PCOS, although the nature of the link between PCOS and diabetes is still not fully understood. Many scientists believe, though, that insulin resistance — when tissues in the body become less sensitive to insulin, which is a large part of the disease process in type 2 diabetes — also plays a role in the development of PCOS. There is also evidence that correcting the hormonal imbalances seen in PCOS may reduce the risk of developing type 2 diabetes. A recent study showed that taking oral birth control pills as a treatment for PCOS reduced the risk for type 2 diabetes. https://www.diabetesselfmanagement.com/news-research/2022/11/16/polycystic-ovary-syndrome-linked-to-higher-risk-for-type-2-diabetes/ XX XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX SAFE TRAVELS to all en route to San Francisco for the Fall 2022 #Diabetes Mine #Innovation Days. Can't wait to see u all in person! Nov 17 and 18 XX XX On the podcast next week.. My daughter Lea talks about siblings and type 1. Last week was all about Eversense E3 and the future of long-term CGM sensors. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Laurin Meyer über das Chaos bei Twitter, eine fulminante Börsenwoche und ein böses Erwachen bei Walt Disney. Außerdem geht es um Bitcoin, Zalando, United Internet, Eli Lilly, Lockheed Martin, BP, Tesla, Novo Nordisk, Sanofi, Zoetis, Pfizer, Allianz Pet and Animal Wellbeing (WKN: A2PBH), General Mills, Tractor Supply Company, Pets at Home-Group und Helvetia. Wir freuen uns an Feedback über email@example.com. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html
T.J. Harvey knows exactly who she is and she's not afraid to let people know it. She's spent her whole career working in the pharmaceutical industry and has learned how to stay true to herself amidst all the corporate demands and deadlines. She shares with Jeanne why how we do things matter; how to be a disruptor for good in your business; why she's so unapologetic about who she is; what failing forward means; the three reasons you need your own “Board of Directors” for your career; and why you should never be silenced. About TJ: T.J. was recently named Vice President, Sales Area Commercial Lead, at Novo Nordisk Inc. With more than 20 years of experience in the pharmaceutical industry, TJ brings extensive breadth and depth of experience in sales leadership managing a diverse mix of products and business models across the primary care, specialty, hospital and vaccines markets. Previously, she was the AVP, US Vaccine Sales and Customer Engagement Organization at Merck Pharmaceutical Company. She held numerous other positions across the organization including Customer Team Leader, Sales Strategic Planning, Director of Commercial Operations, Director of US Learning and Development, Executive Director of Global Human Health (GHH) Compliance, Executive Director of GHH Learning and Development, and Chief Learning Officer. Under her watch as CLO, TJ's organization won multiple awards including Learning in Practice, Excellence in Partnership Award, International EHS Innovation Award and numerous Brandon Hall Excellence awards, to name a few. T.J. is a former alumna of the Women's Leadership Program, past recipient of the prestigious Presidents Award, Global Chair of the League of Employees of African Descent (LEAD), Executive Sponsor for the PA Rainbow Alliance EBRG and is the second recipient of the Merck Women's Leadership Excellence Award. LinkedIn: Tivonnia Harvey
There's a bright future for diabetes technologies, and it's getting closer! In this episode, Liam McMorrow, Senior Project Manager at Novo Nordisk, talks about introducing and scaling innovations in healthcare, especially those that enable access to diabetes technologies. Living with type one diabetes, Liam is very interested in the advancements that happen in diabetes technologies and in improving access to them. He discusses the challenges in a big pharma company when it comes to developing new digital products. At Novo Nordisk, he's seen approaches working with obesity like asynchronous consultations and remote diagnoses that can provide more technology-enabled healthcare services. Tune in to this episode to learn about overlapping pharma and digital health in innovative ways that can boost and improve the consumerization of healthcare! Click this link to the show notes, transcript, and resources: outcomesrocket.health
Alexander Darwall, manager of the European Opportunities Trust, tells us why the European economy is in structural decline, but also why you can still make money there as an investor. He discusses healthcare company Novo Nordisk – in particular, its diabetes drug and new use for weight-loss – tells us about investing too early in Deutsche Boerse, and reveals why his investment in Dark Trace is just a small position today. Alexander also gives his views on central banks: the mistakes they are making and how politicised he thinks they are.What's covered in this episode: Why you don't need to be excited about Europe as an economy, to still make money thereHow the right companies can do well, despite the risk of central bank mistakesThe characteristics of ‘special companies' making up the portfolioWhy the manager invests in Novo NordiskHow a diabetes drug can also help patients lose weightHow Deutsche Boerse can do well in periods of stock market volatilityWhy the cyber security sector is at risk of disruptionMore about this fund:European Opportunities Trust offers investors access to a high conviction portfolio of European equities with a bias towards medium and larger companies. Manager Alexander Darwall generates his own ideas, primarily through company meetings. Firms benefiting from economic tailwinds and in strong positions within their industries are preferred. He particularly likes businesses with proprietary technology and companies that have a business plan that provides them with long-term sustainable growth. He has a record of success in different economic environments.Learn more on fundcalibre.comPlease remember, we've been discussing individual companies to bring investing to life for you. It's not a recommendation to buy or sell. The fund may or may not still hold these companies at the time of listening. Elite Ratings are based on FundCalibre's research methodology and are the opinion of FundCalibre's research team only.
Today we are talking to Ram Aiyer. Ram is CEO of Korro Bio, an RNA base editing company focused on co-opting ADAR, a naturally present editing system in all our cells to base edit A to I (which is translated as a G) in RNA. Prior to Korro, Ram was CBO and CFO of Corvidia, a company he successfully helped build and sell to Novo Nordisk for 2.1Bn$. Prior to Corvidia he was an EIR at BioHealth Innovation. He started his scientific career at Janssen Pharmaceuticals and held leadership roles at FlowMetric, Sofinnova Partners, and JP Morgan Chase.Today we discuss his path to becoming the CEO of a biotech company, the transition for a first time CEO, his success at Corvidia, running a leading biotech company in today's markets and the science/technology & culture underpinning Korro.
Dagens erhvervsoverblik: Novo Nordisk ryger ned på 4. pladsen på dette års liste over Top 1000 danske virksomheder målt på omsætning. Bred enighed om at løfter om støtte og hjælp til energi-regningsplagede danskere skal finansieres krone til krone. Danske virksomheder er godt polstrede til at imødegå en recession. Vært: Sofie Rud (firstname.lastname@example.org)
Eisai and Biogen's Alzheimer's disease drug lecanemab did surprisingly well in a phase 3 trial. The results support the idea that an anti-amyloid drug like lecanemab could be a way to treat Alzheimer's—a hypothesis that has been under fire since Biogen's debacle with its approved anti-amyloid med, Aduhelm. And, while lecanemab's approvability isn't being debated—unlike the case with Aduhelm after its phase 3 program read out—commercial reimbursement could still be a challenge for the Eisai drug. We'll also talk about football, or at least Pfizer's COVID vaccine ad campaign that kicked off during the NFL season. The company's marketing strategy over the last almost two years has changed over time and with various approvals. Recently, Pfizer ramped up its campaign with branded advertising for shots in teens, but its NFL season push is focused on its new, tweaked booster vaccine and takes a more subtle approach but with big money behind it. To learn more about topics in this episode: It's a hit: Eisai springs 'major surprise' with phase 3 win for Biogen-partnered Alzheimer's drug Eisai and Biogen's phase 3 Alzheimer's win puts amyloid back in the driver's seat, for now Editor's Corner: Eisai and Biogen need to meet CMS halfway after lecanemab's Alzheimer's clinical trial win NFL season sees Pfizer kick off major Comirnaty COVID vaccine ad offensive for teens, boosters Pfizer offers a soft sell with a strong message on vaccines in first COVID ad The inside story behind Pfizer and BioNTech's new vaccine brand name, Comirnaty Sign of the times? US stocks up on Amgen's radiation sickness drug Nplate Capacity to spare: US has manufacturing firepower to crank out more essential medicines, researchers say Illumina pitches $200 genomes with new line of DNA sequencers Novo Nordisk ready to submit once-weekly insulin to FDA after scoring final phase 3 win Ocaliva fails NASH trial just as Intercept charts path toward FDA application The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.
It's “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: Michigan joins California in exploring producing and distributing insulin made in-state, new study looks at why girls have a harder time with T1D than boys, weekly basal insulin moves forward, Dexcom puts G7 in wider release (but not yet in the US) and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Michigan following California when it comes to exploring making and distributing insulin. Governor Gretchen Whitmer signed an executive directive this week to establish a Michigan-based insulin manufacturing facility, and facilitate the development, in conjunction with a partner or partners, of a low-cost insulin product for distribution in Michigan. Whitmer already announced a plan to cap insulin costs in her State of the State address in January. https://michiganadvance.com/blog/whitmer-signs-directive-seeking-to-lower-insulin-costs-wins-bipartisan-praise/ XX Novo Nordisk plans to move forward with its once a week insulin icodec. Recent studies show it worked as well or better than daily basal insulin, reducing A1C after 52 weeks. Novo Nordisk's ONWARDS program for once-weekly insulin icodec comprises six phase 3a global clinical trials, including a trial with RWE involving more than 4,000 adults with type 1 or type 2 diabetes. It is expected that Novo Nordisk will file for regulatory approval of the once-weekly insulin icodec in the first half of 2023 in the US, the EU, and in China. There is a separate and additional study for people with type 1 – looking at weekly insulin icodec wth mealtime insulin. That's expected to conclude in about six months. https://pharmaphorum.com/news/novo-nordisk-achieve-headline-results-with-icodec-insulin/ XX Big new study shows that girls tend to have more serious issues with type 1 diabetes than boys. This is physical, quantifiable stuff, including higher blood sugar levels, weight issues, and higher cholesterol. This was a review of 90 previous studies at Amsterdam University Medical Centers. that women and girls have typically not received as much attention as study subjects as men. These researchers say more study is needed including finding ways to help doctors treat girls with type I diabetes differently than boys https://www.healthline.com/health-news/why-type-1-diabetes-can-be-tougher-on-girls-than-boys XX Alarming new study says that cases of type 1 worldwide could double by 2040. Tracking has improved in recent years, but Type 1 diabetes is underrepresented. In addition, because many countries don't collect Type 1 diabetes data, the numbers have historically skewed toward North America and Europe. About 175,000 people worldwide died because of Type 1 diabetes in 2021, they believe, and 63 to 70 percent of the deaths in those under age 25 occurred because the disease wasn't diagnosed. This study is in the Lancet Diabetes and Endocrinology https://www.washingtonpost.com/health/2022/10/03/diabetes-type-one-surge/ XX Big new study looking at which drugs paired with Metformin work the best for type 2. The trial was conducted at 36 study centers nationwide with more than 5000 people. Three groups took metformin plus a medicine that increased insulin levels: sitagliptin or Januvia, liraglutide or Victoza, or glimepiride or Amaryl. The fourth group took metformin and a long acting insulin. After about five years of follow-up, the researchers found that all four drugs improved blood glucose levels when added to metformin. But those taking metformin plus liraglutide or the long-acting insulin achieved and maintained their target blood levels for the longest time. The effects of treatment did not differ with age, sex, race, or ethnicity. However, none of the combinations overwhelmingly outperformed the others. https://www.nih.gov/news-events/nih-research-matters/popular-diabetes-drugs-compared-large-trial XX Dexcom's G7 is getting a wider rollout: the United Kingdom, Ireland, Germany, Austria and Hong Kong, with launches in New Zealand and South Africa in the coming weeks. I'll link up the promotional video.. no news yet from the US FDA on when the G7 will be approved in the US. I am talking to Dexcom's Senior Director of Global Product Design for Tuesday's podcast episode. https://www.youtube.com/watch?v=dYqNUf0paAU XX Tandem's t:connect mobile app is now compatible with the latest iOS operating system on version 2.3 of the t:connect mobile app. Until this update, you could lose the mobile bolus if you updated your phone. Tandem also added a new iPhone and nine new android devices to their compatibility list. We'll link that up in the show notes. : https://www.tandemdiabetes.com/.../device-compatibility XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX The College Diabetes Network announces a name change – they'll now be known as the Diabetes Link. The groups says this new name reflects a commitment to expand support to the larger young adult diabetes community, whatever the type of diabetes they live with and whether they're in school or in the workforce. Currently, there are 3 million young adults (ages 17-30) living with diabetes in the U.S. and that number continues to increase every day. The Diabetes Link is the only national organization that focuses specifically on people in their teens and twenties, in recognition that this time of their lives is full of enough change and challenges without a chronic disease added to the mix. XX And finally, another zoo animal with a CGM. Tiana is a lemur in New Zeleand. The zoo's education officer, has diabetes and recommended the Dexcom for the lemur. Interestingly, they aren't using insulin here, but rather a hypoglycemia medication and are altering the lemur's diet. Apparently lemurs are prone to something more like type 2 diabetes due to some iron issues or if they eat too much sugar, but Tiana's case more resembles type 1. https://www.stuff.co.nz/national/130016440/meet-tiana-the-diabetic-lemur-with-a-glucose-monitor-stuck-to-her-back#:~:text=Hamilton%20Zoo%20resident%20lemur%2C%20Tiana,with%20diabetes%20in%20the%20zoo.&text=Zoo%20vet%20Tori%20Turner%20says,Hamilton%20has%20joined%20the%20club. XX On the podcast next week.. Dexcom's Senior Director of Global Product Design – Very We'll talk about what goes into designing a comletley new product like the G7. He lives with type 1 himself. This past episode is all about how diabetes communities around the world stayed connected during the early days of the pandemic, Listen wherever you get your podcasts Hey for you parents, we've got a webinar on Halloween, link in the show notes and on my social media. That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
Hur pratar vi om hälsoförändringar och övervikt? Och går det att skämta om? Hör det 13:e viktiga samtalet med komikern Marika Carlsson. Obesitas – Ett viktigt samtal är en podcast från Novo Nordisk. Programledare: Susanna Dzamic På webbplatsen www.faktaomvikt.se kan du läsa mer om obesitas.
As leaders, how do we adapt to change in the workplace? In this episode, Patricia Bradley shares importance of adapting to change and how leaders need to be open to learning Patricia Bradley is the Global Chief Commercial Officer at MindMaze, a global pioneer in the development of neurotechnology and digital therapeutics (DTx) for neurological recovery and care. With more than 25 years of increasingly impactful roles at MindMaze, Huma, Novo Nordisk, and Neuromedical Systems, Patricia maintains a strong focus on patient-centric, outcomes-focused healthcare solutions. She was recently named Global Chief Commercial Officer for MindMaze. Previously as VP of Sales and VP of Marketing at Novo Nordisk, Patricia built a clinical education startup that was recognized as best in class. Patricia holds an MBA from Wagner College (NY) and a Bachelor's degree with a dual major in Business Economics and Political Science from The State University of New York at Oneonta. In this episode: Patricia shares her background and how she got her start in the digital healthcare Starting a leadership role in sales and learning how to lead while on the role Patricia talks about Nelson Mandela and his leadership style and how it is important to not just be loud but learn how to be powerfully quiet Embracing the work from home setup for employees Key Takeaways: Leaders can be successful when they look in the positive of things Importance of personal connections and how they can be beneficial for both employees and employers Technology will influence how leaders impact the global community Tweetable Quote: “ I do think you have to embrace change and not be afraid of it. Too many people wanna do things the way they did in the past, or they're afraid of new technologies. I think you've got to challenge yourself to always be learning.” - Patricia Bradley Connect with Patricia onhttps://www.linkedin.com/in/havenner/ ( )http://linkedin.com/in/patricia-bradley (LinkedIn), and check out her website https://www.mindmaze.com (https://www.mindmaze.com). Email: email@example.com Website:http://www.leadingchangepartners.com/ ( http://www.leadingchangepartners.com/) Leadership Is Changing Facebook Group:https://www.facebook.com/groups/LeadershipIsChanging/ ( https://www.facebook.com/groups/LeadershipIsChanging/) Leadership is Changing LinkedIn Page: https://www.linkedin.com/company/leadership-is-changing-podcast/ (https://www.linkedin.com/company/leadership-is-changing-podcast/)
Accessibility is one of the greatest challenges facing the healthcare industry in Africa, whether in preventive care, curative care or innovative medicines- but is also its greatest opportunity. Over the past three years, Walter Mibei has been at the forefront of leading efforts in the COVID-19 and Ebola Virus pandemic response in sub-Saharan Africa. He has 12 years of experience since qualifying as a doctor, working with companies such as Johnson & Johnson and Novo Nordisk. He is currently taking a mid-career break which he is spending as a Sloan Fellow at The Stanford Graduate School of Business. In this episode, we look at his transitions over the course of his career and break down the opportunities available for actionable solutions in accessible healthcare to better prepare Africa for the next pandemic. Find out more about Walter through his LinkedIn: https://www.linkedin.com/in/walter-mibei/ Support our podcast further by subscribing to our Patreon Page here: https://www.patreon.com/boardroombanter?fan_landing=true
Two Big Pharma companies, GSK and Takeda, made moves this week to bolster their environmental sustainability efforts. GSK is focusing on its supply chain and Takeda on its electrical sources in the U.S. In GSK's case, the development is part of a larger trend of companies focusing on emissions from outside of their direct operations. Fierce's Fraiser Kansteiner and Eric Sagonowsky will discuss what we can expect on environmental sustainability at Big Pharmas. To learn more about topics in this episode: GSK puts suppliers on the hook as it amps up sustainability crusade A $3M gene therapy: Bluebird bio breaks its own pricing record with FDA approval of Skysona Merck finally gets FDA nod to relaunch HIV trials, but drops preventive therapy plans FDA plans advisory committee meeting to discuss racial bias built into pulse oximeters Smartphone cameras could replace pulse oximeters to measure blood oxygen at home: study Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.
In the latest pharmaphorum podcast, Florian Baeres, Corporate Vice President for global medical affairs at Novo Nordisk, joins editor in chief Jonah Comstock to talk about the innovative once-weekly insulin currently in development and how it could change the game for people currently managing their type 2 diabetes with daily injections.
Det här avsnittet handlar om typ-2-diabetes, en av våra vanligaste folksjukdomar. Vid typ 2-diabetes har kroppen svårt att hålla sockerhalten i blodet normal. Vanliga symtom är bland annat trötthet och att du behöver kissa oftare. Symtomen kommer ofta långsamt och kan ibland vara svåra att märka. Patienten kan ofta göra en del själv för att sänka blodsockervärdet, men ibland behövs läkemedel.Den som ska berätta för oss om typ-2-diabetes är Boris Klanger. Han är specialistläkare inom allmänmedicin och verksamhetschef för Läkargruppen i Västerås. Han är sedan många år en flitigt anlitad expert och föreläsare inom diabetesområdet.Avsnittet presenteras i samarbete med Novo NordiskHär kan du läsa mer om typ-2-2diabetes:https://www.novonordisk.se/novo-nordisk-i-sverige/nollkomplikation/typ-2-diabetes.htmlProgramledare: Fritte FritzsonProducent: Ida WahlströmKlippning: Marcus TigerdraakeSignaturmelodi: Vacaciones - av Svantana i arrangemang av Daniel AldermarkGrafik: Jonas PikeFacebook: https://www.facebook.com/alltduvelatveta/Instagram: @alltduvelatveta / @frittefritzsonTwitter: @frittefritzsonPodden produceras av Blandade Budskap AB och presenteras i samarbete med Acast Become a member at https://plus.acast.com/s/alltduvelatveta. Hosted on Acast. See acast.com/privacy for more information.
In today's episode, Matthew Clemente talks about the product and engineering scaling challenges working in the biomedical industry. Key Takeaways: An overview of the Biomedical Industry Understanding the Biomedical regulatory overhead on the product roadmap Testing and regulatory issues. Acceleration and efficiencies in the development process. Understanding the team's role & risk management. Mission-driven drivers Connect with Matthew Clemente at https://www.linkedin.com/in/prspctvs About today's guest: Matthew Clemente currently serves as the Senior Vice President of Product & Development at Bigfoot Biomedical, responsible for an innovative, emerging portfolio of diabetes care services and technologies transforming existing care models. Matthew previously served as the Corporate Vice President of Delivery Systems Engineering at Novo Nordisk and as the Senior Director and Chief Technology Officer at Eli Lilly & Company, where he led the development of portfolios of connected drug delivery devices, applications, and algorithms that served as the foundation of both drug manufacturers and connected diabetes ecosystems. Before that, he was the Director of Advanced Drug Delivery Systems at Unilife Corporation. He built and managed an integrated engineering and science organization focused on mechanical, electromechanical, digital, and container closure systems for prefilled, preassembled, wearable drug delivery applications. Before Unilife, Matthew held various roles of increasing responsibility at multiple Johnson & Johnson companies. He primarily served in the new product development of insulin pumps at Animas Corporation for J&J's Diabetes Care Franchise. Matthew obtained a Bachelor of Science in Biomedical Engineering from the University of Miami and an MBA in Finance from Villanova University. ________ Thank you so much for checking out this episode of The Tech Trek and if you enjoyed this episode, please take a minute and leave a quick rating and review on the Apple podcast app! Want to learn more about us? Head over at https://www.elevano.com Have questions or want to cover specific topics with our future guests? Please message me at https://www.linkedin.com/in/amirbormand (Amir Bormand)
You get a call from the US Customer border which are telling you that your products are blocked. Why that? Maybe because you have no importer defined for these products. And this is what we will explain to you today on this podcast episode. Stéphen Toupin from Dawa Medical is helping those manufacturers by being their Initial Importer and he will tell you what you should do to remain compliant. Who is Stéphen Toupin? Over the last 27 years, Stéphan has gained a wealth of experience in the Medtech and pharmaceutical industries with Astra Zeneca, Biovail, and Novo Nordisk. Stephan founded Dawa Medical in 2015 to collaborate with foreign MedTech manufacturers to enter and succeed in the massive US market. Dawa Medical is a United States Initial Importer and FDA agent, with warehousing and distribution capabilities. Dawa Medical also offers services for the Canadian and Latin American markets. Who is Monir El Azzouzi? Monir El Azzouzi is a Medical Device Expert specializing in Quality and Regulatory Affairs. After working for many years with big Healthcare companies and notably Johnson and Johnson, he decided to create EasyMedicalDevice.com to help people have a better understanding of the Medical Device Regulations all over the world. He has created the consulting firm Easy Medical Device GmbH and developed many ways to deliver knowledge through videos, podcasts, online courses… His company also acts as Authorized Representative for the EU, UK, and Switzerland. Easy Medical Device becomes a one-stop shop for medical device manufacturers that need support on Quality and Regulatory Affairs. Links Stéphen Toupin LinkedIn Page: https://www.linkedin.com/in/stephantoupin/ Dawa Medical LinkedIn Page: https://www.linkedin.com/company/dawa-medical-llc/ Dawa Medical Website: https://dawamedical.com/ FDA Initial Importer: https://www.fda.gov/medical-devices/device-registration-and-listing/who-must-register-list-and-pay-fee FDA 21 CFR part 803: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=807.3
Tonia Sideri was a data scientist herself before taking on her role as head of Novo Nordisk's AI and Analytics Center of Excellence. Now she's putting her experience to use helping the Danish pharmaceutical company in its quest to develop medicines and delivery systems to treat diabetes and other chronic diseases, such as hemophilia, obesity, and growth disorders. In a highly regulated industry where failures are costly, Tonia's philosophy is to fail fast through what she calls “data-to-wisdom sprints.” These two-week hackathons enable her group to rapidly test the feasibility of new product ideas with input from their colleagues on the business side. Tonia joins this episode to discuss her team's approach to hypothesis testing, the benefits of incorporating design thinking into building data and AI products, and why she believes empathy is the most important skill a data scientist can have. Read the episode transcript here. Me, Myself, and AI is a collaborative podcast from MIT Sloan Management Review and Boston Consulting Group and is hosted by Sam Ransbotham and Shervin Khodabandeh. Our engineer is David Lishansky, and the coordinating producers are Allison Ryder and Sophie Rüdinger. Stay in touch with us by joining our LinkedIn group, AI for Leaders at mitsmr.com/AIforLeaders or by following Me, Myself, and AI on LinkedIn. Guest bio: Tonia Sideri is head of the AI and Analytics Center of Excellence (CoE) at Novo Nordisk, a global pharma company based in Denmark that develops diabetes care products, as well as solutions that target other chronic diseases, such as obesity, growth disorders, and hemophilia. The CoE is a group of data scientists, machine learning engineers, and software developers located within Novo Nordisk's Global IT group who work cross-functionally with the company's machine learning/analytics systems and its machine learning operations platform. Sideri was a data scientist before taking on a management role. She has years of experience in startup incubators and corporate transformation labs, where she helped unlock the potential of data across the banking, pharma, and biotechnology industries and across a variety of business models, including B2C, B2B, and digital native vertical brands. We encourage you to rate and review our show. Your comments may be used in Me, Myself, and AI materials. We want to know how you feel about Me, Myself, and AI. Please take a short, two-question survey.
Heterogeneity across available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes means that agents should be prescribed based on patient characteristics and preferences. So how can we best make that decision? Join Dr Harpreet Bajaj for a discussion of tailoring GLP-1 RA regimens to patient characteristics, including considerations for dosing and treatment intensification. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment. References available here Dr Harpreet Bajaj declares the following financial relationships from the past 24 months: Grants/Research Support: Eli Lilly, Novo Nordisk, Sanofi Liberum IME staff, ACHL staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Target Audience This educational activity is intended for an international audience of non-US and non-UK HCPs. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
Re Perez is many things: a published author, CEO and Founder of an award winning branding business that has an inclusive, equitable staff, emotional intelligence ninja and intuitive master. He also happens to be Filipino and gay. Growing a business being a member of an underrepresented community has different DEIB implications than that of socially dominant groups. How do you walk the fine line of supporting other underrepresented groups, hire the best talent and prevent other kinds of homogenization? Re breaks it down. A point of view you may not have heard before -- don't miss it.More about Re Perez, Branding for the People and his book, 'Your Brand Should Be Gay (even if you're not): Re is a former Fortune 500 Brand Consultant turned Entrepreneur, Keynote Speaker, Best Selling Author, and CEO of Branding For The People, an award-winning branding agency that creates world-class brands that accelerate business growth. Re's storied career includes senior-level positions at top global branding firms, including BrandLink, Interbrand, Reputation Management Institute, and TMP Worldwide, where he gained invaluable experience consulting to Novo Nordisk, Nielsen Company, TD Ameritrade, and Xerox among many other household names. As a keynote speaker, Re electrifies every audience and brings forward-thinking insights, actionable content, and practical tips for every business owner and marketing team. His speaking portfolio includes major entrepreneurial conferences including: EO's Global Leadership Conference, Infusionsoft's ICON and PartnerCon, SellerCon, Traffic & Conversion Summit, and Thrive: Make Money Matter (to name a few). He is also a faculty teacher for Growth Institute. Re holds a degree in Organizational Behavior & Communications from New York University. He has lived in Florida, New York City, Dubai, and San Diego, but currently resides in Austin, TX.His book is called: Your Brand Should Be Gay (even if you're not) – The art and science of creating an authentic brand
The group investigates potential for different combination packages, beginning with Roger's suggestion for an oral semaglutide. Naim notes that there are other combination trials in the works that may provide more insight.The episode then wraps up with Roger's final question: in seven years, what percentage of patients being treated for NASH fibrosis, non-cirrhotic then cirrhotic, will be treated using combination therapies? Naim thinks the majority of patients with NASH cirrhosis will be on combination therapy, and the majority of patients with F2 or F1 fibrosis will be on monotherapy. He also thinks F3 will see a trend of adding more agents over time to prevent progression to cirrhosis. Mazen suggests in seven years we will not get to combo for NASH patients because of regulation, partnership, and logistics. Louise settles for a position between Naim and Mazen. Jörn highlights that many hurdles remain, especially in identifying these patients. Roger agrees that these diagnostics will be hard to scale over the next seven years. He also imagines there to be less combination packages and more step therapy.
This conversation begins with a broader look at the strategies behind developing combination agents and the role these combination therapies will play in what Mazen Noureddin describes as the coming “combo-combo” world.The group agrees that 2 or 3 agents are the most they can see in a combination therapy at this time. They all agree that some patients will require combination therapies while others will succeed with monotherapies. This will be linked with disease severity. Naim also shares another long term study he is working on.
This discussion begins with Naim offering an in-depth look into the mechanics of the recently published combination study. He explains that “semaglutide hits every point” in terms of effects on metabolic syndrome, cardiovascular outcomes, obesity and liver fat, but it has not yet been proven in monotherapy to regress fibrosis. Gilead Sciences had three agents whose potential anti-fibrotic effects the company wanted to explore fully, so Gilead and Novo Nordisk, which owns semaglutide, formed a partnership to develop these drugs.One agent, selonsertib, turned out to be ineffective, but the other two, the FXR agonist cilofexor and the ACC agent firsocostat proved efficacious in combination with semaglutide. Naim goes on to describe the mechanics of the study and presents results demonstrating that even in a six-month trial, the triple therapy proved efficacious with a favorable side effect profile.Jörn notes one very important aspect of combination agents: by requiring lower levels of each individual agent, they have the potential to exhibit superior safety and side effect profiles that a higher-dose monotherapy might.The rest of this conversation features additional comments by Mazen, namely addressing the short duration of the study. He suggests that if extended, the study quite possibly had more positive results to be shown, namely, through further weight loss. Mazen also raises an intriguing prospect with an interesting acknowledgment: this is an open-label study with neither biopsies nor a placebo arm. However, he suggests, this kind of design will become far more prevalent in a future when one agent in the study has already been approved and is widely used with patients.
Naim opens this conversation with his hope for finding eventual combination therapies that begin to realize a cure for NASH in some patients. In particular, he is encouraged to see so many patients achieve greater than 30% relative fat reduction in such a short study. Louise notes that the ability to show patients “real-world results” quickly will motivate them to maintain therapy and lifestyle modification.The discussion shifts to the inclusion of NITs in these combination therapies, and the need for sound pricing strategies. Naim proposes a 6-month “futility” standard: if the drug does not provide results in 6 months, discontinue. Roger notes the importance of combination therapy in a disease that has so many theoretical target points and pathways within the liver.
The discussion shifts to the challenges behind collaborating in a field that, as Naim puts it, “no one has figured out what to do with.” Mazen calls on the “larger companies” to work with the smaller ones to make these studies more common, noting that the economics and risk profiles of smaller companies require them to focus on getting a single drug to market as quickly as possible. Naim notes that precedent has taken form in Hepatitis C. It was very difficult to treat and different companies' drugs were combined for a while until each company figured out their own combination and that collaboration stopped.A debate next emerges when Naim describes LEGEND, a trial combining the promising PPAR agonist with the SGLT-2 agent, empagliflozin. Naim describes empa as an excellent agent to counteract potential weight gain with lani. Mazen shares his belief that the trial should have combined lani with a drug that provides greater weight loss, possibly a GLP-1 agonist or dual agonist. Roger suggests it depends on the target: liver and metabolic disease targeting might lead to a PPAR/GLP-1 combination, while a more holistic look at metabolic outcomes might prefer SGLT-2s for their proven beneficial effects on kidney and cardiovascular diseases.
This episode explores the future of combination agents in NASH Therapy. First author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). While the conversation starts by focusing on this article, the discussion itself takes a far broader look at the strategies behind developing combination agents, the likely role these combination therapies will play in treating patients, and, more generally, what Mazen Noureddin describes as the coming “combo-combo” world.At the outset, Naim notes that while this study was published in 2020, it was first presented at AASLD in 2020. The rationale? As he explains, “semaglutide hits every point” in terms of effects on metabolic syndrome, cardiovascular outcomes, obesity and liver fat, but has not yet been proven in monotherapy to regress fibrosis. Novo Nordisk and Gilead Sciences had formed a partnership to develop NASH drugs, and Gilead had two agents with anti-fibrotic effects, the FXR-agonist cilafexor and the ACC agent firsocostat, that might regress fibrosis.This conversation is dense with excellent questions and important observations. Here are some of them:Jörn notes one very important aspect of combination agents: by requiring lower levels of each individual agent, they have the potential to exhibit superior safety and side effect profiles that a higher-dose monotherapy might. In agreeing, NAIM notes with particular enthusiasm how many patients achieved greater than 30% relative fat reduction in such a short study.Mazen raises an intriguing prospect by starting with an interesting acknowledgment: this is an open-label study with neither biopsies nor a placebo arm. However, he suggests, this kind of design will become far more prevalent in a future when one agent in the study has already been approved and is widely used with patients.Louise notes that the ability to show patients “real-world results” quickly will motivate them to maintain therapy and lifestyle modification.Naim proposes a 6-month “futility” standard: if the drug does not provide results in 6 months, discontinue.Roger notes the importance of combination therapy in a disease that has so many theoretical target points and pathways within the liver.Mazen calls on the “larger companies” to work with the smaller ones to make these studies more common, noting that the economics and risk profiles of smaller companies require them to focus on getting a single drug to market as quickly as possible.A debate emerges when Naim describes LEGEND, a trial combining the promising PPAR agonist with the SGLT-2 agent, empagliflozin. Naim describes empa as an excellent agent to counteract potential weight gain with lani. Mazen shares his believe that the trial should have combined lani with a drug that provides greater weight loss, possibly an GLP-1 agonist or dual agonist. Roger suggests it depends on the target: liver and metabolic disease targeting might lead to a PPAR/GLP-1 combination, while a more holistic look at metabolic outcomes might prefer SGLT-2s for their proven beneficial effects on kidney and cardiovascular diseases. The group agrees that 2 or 3 agents are the most they can see in a combination therapy at this time. They all agree that some patients will require combination therapies while others will succeed with monotherapies. This will be linked with disease severity.There are more observations here and a raft of supporting data points and arguments. We lack sufficient space to cover all these in this summary, so read and enjoy yourself!
Podcast Series Title: The 411 on a GLP-1Podcast Series Description: Join series host Dr. Jim Gavin, Clinical Professor of Medicine at Emory University and Chief Medical Officer for Healing our Village in Atlanta, Georgia, and fellow leaders in the field of diabetes as they tackle some of the challenges we face when treating T2D. Topics of discussion include clinical inertia, as well as the mechanism of action, dosing, efficacy, and safety of a GLP-1 RA for adults with T2D.Episode Title: How to Empower Patients with T2D Knowledge and Introduce a GLP-1 RAEpisode Description: What do you need to know about a once-daily GLP-1 RA and what can you do to help your patients taking this T2D therapy? Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D. This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.Faculty Presenters:James R. Gavin III, MD, PhDClinical Professor of Medicine, Emory UniversityChief Medical Officer, Healing Our Village, Inc.Atlanta, GeorgiaJeff Unger, MD, FAAFP, FACEDiplomate, American Board of Family PracticeAssistant Clinical Professor of Family Medicine, UC Riverside School of MedicineRiverside, CaliforniaDirector, Unger Concierge Primary Care Medical GroupRancho Cucamonga, CaliforniaCurtis L. Triplitt, PharmD, CDCES, FADCESClinical Associate Professor of Medicine Division of DiabetesUniversity of Texas Health at San AntonioTexas Diabetes Institute, part of the University Health SystemSan Antonio, Texas
In today's episode, we will be talking with Serena Valentine about peer support for those who have chronic illnesses due to diabetes. Serena will talk about the importance of finding support for anyone who has diabetes and how to transition to your new lifestyle. Ms. Serena Valentine is the Executive Director of CORE Initiative, a health & wellness education nonprofit organization in Houston, TX. She is a diabetes peer educator with Cities Changing Diabetes, a global initiative that is managed by Novo Nordisk. Ms. Valentine works with Prevent Blindness to promote eye health and bring awareness to the connection between diabetes & vision loss. Her mantra is, “What you don't know, CAN hurt you….”. QOTD: How has peer support helped you live with diabetes? On this Episode You Will Learn: How important is it for someone who is suffering from a disability due to diabetes to reach out for peer support? What exactly does a Diabetes support group do? How difficult is it for most people to transition back into an independent life? Connect with Yumlish! Website Instagram Twitter Facebook LinkedIn YouTube Connect with Serena! Website Instagram Facebook LinkedIn TikTok YouTube Key Points: 0:00: Intro with Shireen: 1:26: Introducing Serena Valentine 2:48: How important peer support is 5:28: What does a peer support group do 10:38: How to connect with someone in a peer environment 13:23: How difficult is it for someone who has dealt with those types of complications to actually go back and try to lead an independent life? 17:10: Advice for those who are newly diagnosed with diabetes 20:13: Stigmas attached to people with diabetes 23:37: How important is it for family or significant others to be a part of this new lifestyle post diagnosis? 26:41: Where to connect with Serena 28:58: Wrap-Up and QOTD 29:37: Outro with Shireen --- Send in a voice message: https://anchor.fm/yumlish/message
SUPPORT THE PODCAST - https://anchor.fm/dailystockpick/support The energy stocks I have are flying and still have some legs to get back to the June highs. $Cop $Dvn $Oxy $Xom $Cvx $Fang $CRWD - could have some legs with the $PANW earnings - but it's still more expensive Cruise lines like $NCLH have been flying $TSLA split … i should have mentioned but it was clear retail would wake up and think tesla was on sale and the stock would go up $INTU earnings were good … father owns this one … it's been crazy good Look at $drv $PTON - down on earnings - heavy losses on their earnings but it's a turn around story - I like this $MELI - not sure about this one right now - they call it the Amazon of Latin America $NVO - Danish pharma giant Novo Nordisk, they are actually the largest antidiabetic drug company in the world. $CRM still a great long term buy $SNOW crazy good buy under $200 - crazy good quarter with customer growth, contract growth - etc. $NVDA earnings - they pre announced how bad it was - buy on weakness Ron baron said this is a generational time to buy stocks like every pullback before $BABA $APPH $Fcx $Clf $Orcl $Qcom $Spg $Unh $Cost $UPRO - bull $SPXU - bear $SPXL - bull $TQQQ - bull $SQQQ - bear $SARK - bear SCANS $DE - good move up but it's too rich for me right now $HESM - interesting - but not an obvious run F$CX - not huge - but commodities have been making a move back $KHC - interesting in this mainstay POSTED TESLA CHART ON TWITTER SHOWING SPLIT IN AUG 2020 --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/dailystockpick/support
Dagens erhvervsoverblik: Store danske virksomheder tror ikke på de kommer tilbage til Rusland. Boligrenterne brager op og 5 pct.-lånet åbner igen. Dollar på niveau med euro. Novo Nordisk-chef ser klar arvtager til storsælgende middel. VW sætter ord på krisen. Vært: Lasse Ladefoged (firstname.lastname@example.org)
Podcast Series Title: The 411 on a GLP-1Podcast Series Description: Join series host Dr. Jim Gavin, Clinical Professor of Medicine at Emory University and Chief Medical Officer for Healing our Village in Atlanta, Georgia, and fellow leaders in the field of diabetes as they tackle some of the challenges we face when treating T2D. Topics of discussion include clinical inertia, as well as the mechanism of action, dosing, efficacy, and safety of a GLP-1 RA for adults with T2D. Episode Title: What T2D Therapy Have You Considered for Your Patients After Metformin?Episode Description: How common is treatment inertia in the treatment of adult patients with T2D and what can be done about it? Join a multidisciplinary panel including Jim Gavin, MD, PhD; Steve Vacalis, DO; and Jodi Strong, DNP, CDE, BC-ADM, CPT as they discuss and share their insights on the issues surrounding therapeutic inertia. They will also evaluate when to use a GLP-1 RA, and a clinical trial comparing the efficacy and safety of a GLP-1 RA versus a DPP-4i.This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.Faculty Presenters:James R. Gavin III, MD, PhDClinical Professor of Medicine, Emory UniversityChief Medical Officer, Healing Our Village, Inc.Atlanta, GeorgiaJodi Strong, DNP, CDCES, BC-ADM, CPTAspirus Medical GroupStevens Point, WisconsinSteve Vacalis, DOSenior Lead PhysicianCaroMont Family Medicine, CaroMont Regional Medical Center Gastonia, North Carolina
The last two years have provided updated guidelines on management of chronic kidney disease in type 2 diabetes alongside new regulatory approvals of pharmacotherapies. In this episode we speak to Dr David Cherney about the implications of these updates and advancements. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References available here Disclosures: Dr David Cherney declares the following financial relationships from the past 24 months: Honoraria: Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene and Novo-Nordisk Grant/Research support: Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, and Novo-Nordisk. Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.
The past year has included the release of new guidelines on cardiovascular disease prevention and further data on cardioprotective agents in type 2 diabetes. In this episode we speak to Prof. Naveed Sattar about these guidelines and how best to help people with type 2 diabetes to reduce their cardiovascular risk. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References available here Disclosures: Prof. Naveed Sattar declares the following financial relationships from the past 24 months: Advisory - Afimmune, Amgen, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi Consulting - Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi Speaker honoraria - Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi Grant funding - AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Efpeglenatide for type 2 diabetes Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
Members taking specialty drugs represent about 2% of any given employer's population but often consume as much as 30% of an employer's total cost of care. As Pramod John, PhD, in EP353 has said, this isn't just small companies we're talking about here. Some of the largest employers in the US are dropping big bucks on specialty drugs, and they are obviously overpaying and don't need to. No employer or plan really need pay any more than the pharmacy's acquisition price plus a reasonable professional fee. But so many employers pay way more than that. Let's just keep in mind that specialty pharmacy spend extends beyond just pharmacy spend. Medical claims for pharma drugs that are infused, for example, can be more than 50% of an employer or plan's specialty pharmacy spend. What I'm talking about now is buy and bill–type stuff where a hospital or physician practice bills for an infused pharmaceutical product under a patient's medical benefit. Listen to EP370 with Autumn Yongchu and Erik Davis about how some hospitals, for example, are managing to charge employers 6x the cost of specialty meds to infuse them and also EP365 with Scott Haas about PBM shenanigans. So, currently, specialty pharmacy spend is big; but it's grown bigger every single year. Every year, employers and the government/taxpayers alike spend more and more on these really expensive drugs. As you can see, there are billions and billions of dollars on the specialty pharmacy table here. Also, as you certainly know if you've listened to the recent series of specialty pharmacy shows that we've done lately, it's kind of a war out there. There are multiple healthcare industry stakeholders trying to capture all of the money. If you can get your hands on a specialty pharmacy patient and manage their care—or, probably more pointedly, manage to bill for their care—it can be incredibly profitable. This show kind of wraps up some loose ends for me. In this healthcare podcast, I'm speaking with Mike Baldzicki, who is chief brand officer over at AscellaHealth. A majority of Mike's background is in specialty pharmacy infusion, capabilities with an array of different healthcare companies. So, he is a great guy to wrap up some of these loose ends with. On the show today, we discuss how many/the percentage of self-funded employers who have taken their specialty pharmacy business from the “Big Three” or “Big Five” PBMs, how many of them have actively started steering their members and managing their benefit carefully. I talk with Mike about what these employers are doing and how they are doing it. From there, the conversation, of course, naturally flows into preventing hospitals from rapaciously buying and billing, which then segues into a discussion about hospital strategy … because if you can't do your buy-and-bill thing for a whole bunch of your patients, then it makes sense for you to do two things strategically: (1) stand up your own specialty pharmacy and/or (2) set up your own network of infusion centers. Mike and I talk about this. We also discuss how much trying to get a specialty pharmacy drug sucks for most patients, which I deeply investigated in EP337 with Olivia Webb. Also in this episode, you can hear me contend that maybe if Pharma and payers enter into outcomes-based contracts, maybe patients would be better served. It's kind of the pharmacy version of the whole “let's pay for value, not volume” thing. I ask Mike how many pharma outcomes-based contracts are out there in the wild, for reals. All of this and more … but you gotta listen to the podcast. Oh, by the way, acronym alert: SPP stands for specialty pharmacy provider. You can learn more at ascellahealth.com. Michael J. Baldzicki, CRCM, is chief brand officer (CBO) at AscellaHealth. As CBO, Mike supports the AscellaHealth Family of Companies comprehensive business strategy to increase brand awareness, boost perceived value, and improve lines of services in the marketplace. He is responsible for oversight of their Family of Companies based on sales and marketing to finance, client services, and specialty pharmacy strategies throughout the organization that drive strategic business initiatives. Within his roles, he enhances the success of the strategic projects and applies business development, contract negotiations, network advancement, and marketing and outreach strategies that cultivate opportunities for AscellaHealth and their Family of Companies. With more than 24 years of experience, Mike held roles in senior executive management within the specialty pharmacy supply group, pharmaceutical and biotech industry of managed markets, group purchasing organizations, specialty wholesale, and integrated delivery networks. He assumed roles within the pharmaceutical organization such as Bristol Myers Squibb, Enzon BioTech, Novo Nordisk, Baxter BioScience, as well as roles within the distribution channel of AmerisourceBergen specialty groups, BioMatrix Specialty and Infusion Rx, Diplomat/BioRx Specialty Pharmacy, CareCentrix Medical Infusion, Asembia GPO, Axelacare Infusion, to other manufacturer and specialty pharmacy home infusion companies. Mike is active in the biotech community and is council advisor of the Council of Strategic Healthcare Advisors (CSHA), an advisor/faculty member of the Academy of Managed Care Pharmacy (AMCP) for Specialty Pharmacy Advisory Group & Biosimilars Partnership Forum, NCPDP Specialty Pharmacy Stakeholder Action Group, Self-insured Institute of America (SIIA) advisor, National Alliance of Healthcare Purchaser Coalitions, and was 2014 Editorial Board Member for Specialty Pharmacy Times. Mike holds a bachelor's degree in business management and a Certificate in Clinical Research Compliance and Management (CRCM). He has completed programs in leadership development at Harvard University, Brooks Group, Miller Heiman Account Management, and MD Anderson Center Cancer Courses. 04:27 Is it a conflict of incentives to worry about the cost of million-dollar pharmaceuticals? 06:24 “Really, does it make sense to carve up my specialty pharmacy benefit … away from my typical PBM model?” 06:48 What's the trend line with moving away from the big PBMs? 07:20 Specialty pharmacy episodes.07:53 How does a small PBM contract with Pharma? 08:34 EP365 with Scott Haas.10:15 EP337 with Olivia Webb.11:32 “We're still lacking the overall insight to data.” 12:15 “When you have insight and good data, then you can start really driving the plan language and cover requirements.” 13:07 “It is a frustrating game because … the large PBMs that have traditionally managed an employer's spend … doesn't give them the data that's needed.” 13:48 What's going on with outcomes-based contracts? 14:16 What's the importance of aligning reimbursement around value instead of volume? 14:57 “The issue is, how real is the data?” 19:24 EP370 with Erik Davis and Autumn Yongchu.20:36 Are hospital-based specialty pharmacies teaming up with big PBMs? 22:01 “It's market ownership.” 29:17 EP369 with Keith Hartman, RPh.30:43 “These are real scenarios that are happening in the self-insured planned sponsor market.” 30:59 “Employers really should start recognizing organizations that take more of an integrated and thoughtful approach.” You can learn more at ascellahealth.com. Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast Is it a conflict of incentives to worry about the cost of million-dollar pharmaceuticals? Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast “Really, does it make sense to carve up my specialty pharmacy benefit … away from my typical PBM model?” Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast What's the trend line with moving away from the big PBMs? Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast How does a small PBM contract with Pharma? Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast “We're still lacking the overall insight to data.” Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast “When you have insight and good data, then you can start really driving the plan language and cover requirements.” Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast “It is a frustrating game because … the large PBMs that have traditionally managed an employer's spend … doesn't give them the data that's needed.” Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast What's going on with outcomes-based contracts? Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast What's the importance of aligning reimbursement around value instead of volume? Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast “The issue is, how real is the data?” Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast Are hospital-based specialty pharmacies teaming up with big PBMs? Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast “It's market ownership.” Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast “These are real scenarios that are happening in the self-insured planned sponsor market.” Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast “Employers really should start recognizing organizations that take more of an integrated and thoughtful approach.” Mike Baldzicki of @AscellaHealth discusses #specialtypharma, #PBM, #hospitals, #employers, and #pharma on our #healthcarepodcast. #healthcare #podcast Recent past interviews: Click a guest's name for their latest RHV episode! Lisa Bari, Betsy Seals (EP375), Dave Chase, Cora Opsahl (EP373), Cora Opsahl (EP372), Dr Mark Fendrick (Encore! EP308), Erik Davis and Autumn Yongchu (EP371), Erik Davis and Autumn Yongchu (EP370), Keith Hartman, Dr Aaron Mitchell (Encore! EP282), Stacey Richter (INBW34), Ashleigh Gunter, Doug Hetherington, Dr Kevin Schulman, Scott Haas, David Muhlestein, David Scheinker, Ali Ucar, Dr Carly Eckert, Jeb Dunkelberger (EP360), Dan O'Neill, Dr Wayne Jenkins, Liliana Petrova, Ge Bai, Nikhil Krishnan, Shawn Rhodes, Pramod John (EP353), Pramod John (EP352)
Kan juli måneds store rebound holde? Der opstår uenighed i studiet om, hvorvidt aktiebunden er nået, og hvad resten af året vil byde på. Derudover gennemgår Hansen og Larsen regnskaber fra Meta, Netflix, Google, Microsoft, Amazon og Apple samt danske selskaber som Novo Nordisk, Mærsk, DSV, Vestas og Ambu. 00:00 - 00:45 Intro 00:45 - 10:35 Sommer rebound - holder bunden og opturen? 10:35 - 14:44 Store amerikanske regnskaber fra Meta, Netflix, Google, Microsoft, Amazon, Apple - bedre end ventet 14:44 - 27:37 De danske regnskaber fra Novo Nordisk, Mærsk, DSV og Ambu - gode, men blandet kursreaktion 27:37 - 28:06 - Afslutning
Dicke Dividenden machen noch lange kein gutes Investment. Aber nach den Turbulenzen der letzten Monate locken nun einige Top-Unternehmen mit stattlichen Renditen. Tobias Kramer und Christian W. Röhl stellen jeweils drei aktuelle Kauf-Kandidaten vor – darunter einen deutschen Logistik-Champion, einen US-amerikanischen Technologie-Dino und einen britisch-australischen Bergbau-Riesen. Dazu gibt‘s ein Update zur im Scalable Broker derzeit wieder besonders eifrig besparten BASF sowie kurze Einschätzungen zu Allianz und Novo Nordisk.
Millionærklubben tager fat på endnu en børsdag med bl.a. aktuelle regnskabstal fra Novo Nordisk og en nedjustering fra Ambu. Bodil Johanne Gantzel tjekker stemningen og søger efter interessante investeringsmuligheder sammen med aktieanalytiker Lau Svenssen og direktør i Juul Value Invest, Per Juul.See omnystudio.com/listener for privacy information.
In the cybersecurity space, hackers have been able to target and steal an estimated $5.2 million in crypto assets from the Solana ecosystem in the last 36 hours, affecting some 7,900 wallets. ZeroFox CEO James Foster gives his thoughts on the story. Plus, as the diabetes crisis grows, Novo Nordisk is trying to help. CEO Lars Jorgensen discusses the company's earnings. And, treasuries have seen a rapid rise this year. Envestnet's Dana D'Auria and Charles Schwab's Jeff Kleintop dive into the inflation outlook.
TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Kenneth Cusi, MD, FACP, FACE, Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism from The University of Florida about managing nonalcoholic fatty liver disease.Listen in as they discuss considerations with managing nonalcoholic fatty liver disease (NAFLD)...including risk factors, screening, and treatment options.You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversityDouglas S. Paauw, MD, MACP, Professor of Medicine at the University of Washington School of MedicineCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Cusi reports relevant financial relationships with Echosens, Inventiva, Nordic Pharma, Novo Nordisk, Poxel, Zydus (grants/research support); Ionis, Janssen, Genentech, Gilead, Madrigal, Merck, Novo Nordisk, Pfizer, Poxel, Terns Pharmaceuticals (consultant). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.Pharmacist's Letter offers CE credit for this podcast. Log in to your Pharmacist's Letter account and look for the title of this podcast in the list of available CE courses.If you're not yet a Pharmacist's Letter subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.
Millionærklubben er tilbage efter en god, lang ferie og tager fat på dagens marked med Bodil Johanne Gantzel og Lau Svenssen i studiet - klar til en uge, der bl.a. byder på regnskaber fra AP Møller Mærsk og Novo Nordisk og “Kongen af nøgletal”, Nonfarm Payrolls fra USA. Med på telefonen er også Michael Friis Jørgensen og Mads Christiansen om porteføljer og markedsstemning. See omnystudio.com/listener for privacy information.
Zapraszam Was na nowy, piąty odcinek z cyklu rozmów pod tytułem POROZMAWIAJMY SZCZERZE O OTYŁOŚCI. Moim gościem jest profesor Mariusz Wyleżoł - bariatra, z którym porozmawiamy między innymi o tym, czy bariatryczne operacje to droga na skróty lub operacje z zakresu chirurgii estetycznej. Czy wreszcie jest to metoda leczenia, która na ten moment uznana jest za jedną z najbardziej skutecznych metod leczenia otyłości? Nie każdy chory może z niej jednak skorzystać. Jakie ma zatem dostępne opcje terapeutyczne? Zapraszam serdecznie, szczególnie, że temat jest mi bardzo bliski.
On this episode, we discuss an all-too-often underdiagnosed disease: NASH, a.k.a. nonalcoholic steatohepatitis, a severe form of “fatty liver” disease. Though NASH can affect people who are obese or diabetic with high cholesterol, it can also hit someone who's relatively healthy and who doesn't even drink alcohol. It's because of this and other factors that liver disease can be easily underdiagnosed, leading to dire consequences.A few months ago, there was a great roundtable discussion about approaches to care and treatment – and hopeful early diagnosis – for people with NASH. In April 2022, NCQA together with a team from Novo Nordisk published a white paper summarizing this roundtable. The paper was titled "A Rallying Cry: Improving Coordinated Care for People With Nonalcoholic Steatohepatitis."In our interview, we hear from Donna Cryer, President & CEO of the Global Liver Institute, and Dr. Mary Barton, NCQA Vice President for Performance Measurement, exploring new ideas for optimal primary care for liver patients.Donna Cryer, JD, is Founder and Chief Executive Officer of Global Liver Institute (GLI), the premier patient-driven liver health nonprofit operating with offices and partnerships across five continents. Moved by her own experience as a 27-year liver transplant recipient, Mrs. Cryer serves as a fierce advocate for the transformative potential of patient engagement in health policy, research, data, and system design.Mrs. Cryer serves on numerous committees and boards, including the Boards of Directors for the Council of Medical Specialty Societies (CMSS), Sibley Memorial Hospital/Johns Hopkins Medicine, and the Color of Crohns and Chronic Illness (COCCI). She holds an undergraduate degree from Harvard and a Juris Doctorate from the Georgetown University Law Center.Dr. Mary Barton, MD, serves as NCQA's Vice President for Performance Measurement. In her role, Dr. Barton oversees the development, use and maintenance of techniques NCQA uses to evaluate health care quality. She ensures the scientific integrity of NCQA measurement and research. She also leads NCQA in winning and executing health care quality measurement contracts for federal and state governments.
Biopharma watchers have been speculating for weeks about Merck & Co. buying out fellow cancer drugmaker Seagen. But now, the two companies are reportedly nearing a deal. We'll discuss how it could be the largest biopharma deal since 2020—and what might stand in its way. But that's not all. Every year Fierce puts together a special report ranking the highest-paid biopharma CEOs of the year – and this year is no different. We'll cover that, plus this week's headlines. To learn more about the topics in this episode: Merck said to near $40B deal to buy Seagen. But will FTC rain on their parade? The 15 highest paid biopharma CEOs of 2021 FDA lets pharmacists prescribe Pfizer's Paxlovid, easing access to the COVID antiviral FDA is letting pharmacists prescribe Pfizer's Paxlovid but won't do the same for Merck's Lagevrio 'Organize. Align': Women in biotech see Roe v. Wade ruling as a call to action SEC charges ex-Mazor exec with insider trading over $1.6B Medtronic buyout Game on, Hemlibra. Novo Nordisk's attempt to snatch Roche's hemophilia crown gets serious The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts. See omnystudio.com/listener for privacy information.
Blandine Lacroix, Corporate Vice President, Strategy & Rare Disease at Novo Nordisk, shares the 3 things that she believes make an inclusive leader, the power of bringing your whole self to work and the power of a human-centric approach to leadership.
Another ASCO and more CAR-T data. Arcellx presented early results on its multiple myeloma therapy at last weekend's ASCO annual meeting, and we dig into what it would take to stand up to J&J's Carvykti. But that's not all. People were on their feet for the Enhertu breast cancer drug and its unheard-of results. We've got a lot to share about ASCO. Also under discussion is Fierce's special report on the rising stars in the medtech and healthcare fields and what they have in common. Lastly, we finally have boots-on-the-ground at an industry conference. Our reporter headed out to the first in-person ASCO since the pandemic started. She planned to learn about new data releases and discoveries, and also found out something surprising about herself. To learn more about the topics in this episode: Fierce Healthcare and Fierce Medtech's 17 rising stars in health tech ASCO: AstraZeneca, Daiichi's Enhertu could transform breast cancer treatment with landmark HER2-low show ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt ASCO: ‘Any way you slice' it, Arcellx's CAR-T is matching J&J-Legend's Carvykti, analyst says ASCO: Medidata links CAR-T's cytokine release syndrome risk to common biomarkers in new study ASCO: Black breast cancer patients want to participate in trials, but adequate information is hard to come by Emergent says J&J owes up to $420M for breach of contract. J&J: You want to talk breaches? ADA: Eli Lilly's stellar tirzepatide weight loss data tee up showdown with Novo Nordisk's Wegovy, analysts say ADA: With promising long-term data for its artificial pancreas, Medtronic aims to fully close the diabetes management loop UPDATE: Bristol Myers strikes up Roche rivalry with $4.1B Turning Point buy Eli Lilly wins key dispute over patient warnings in era of DTC advertising ASCO: Return to in-person 'zoo that it always was,' with added COVID challenges—and bad shoes The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. See omnystudio.com/listener for privacy information.
It's "In the News.." got a few minutes? Get caught up! Top stories this week: The Federal Trade Commission probes the prescription drug middleman industry, once a week basal insulin moves forward, DIY insuln dosing systems get a thumbs up at ADA Scientific Sessions, Sernova's stem cell system releases great findings and more! Learn more about the T1D Exchange Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX The Federal Trade Commission will launch an inquiry into the prescription drug middleman industry.. requiring the six largest pharmacy benefit managers to provide information and records. They're looking at PBMs such as CVS Caremark; Express Scripts, Inc.; OptumRx, Inc.; Humana Inc and more. The largest PBMs are now vertically integrated with the largest health insurance companies and wholly owned mail order and specialty pharmacies. In these roles, pharmacy benefit managers often have enormous influence on which drugs are prescribed to patients, which pharmacies patients can use, and how much patients ultimately pay at the pharmacy counter. https://www.ftc.gov/news-events/news/press-releases/2022/06/ftc-launches-inquiry-prescription-drug-middlemen-industry?utm_campaign=https://www.ftc.gov/news-&utm_content=1654622484&utm_medium=social&utm_source=twitter XX Confirming what many of you have known for years.. an open-source automated insulin delivery system -- also known as a do-it-yourself system -- was both safe and effective for patients with type 1 diabetes. This is from the CREATE trial, designed to test DIY system, presented for the first time at the ADA Scientific Sessions. This system was made up of the OpenAPS algorithm from a version of AndroidAPS implemented in a smartphone, paired with the DANA-i insulin pump and Dexcom G6 continuous glucose monitor. The researchers previously published additional information in the Journal of Diabetes & Metabolic Disorders. https://www.medpagetoday.com/meetingcoverage/ada/99109 XX Stem cell study showing great results. Sernova says the first three patients of six total continue to be insulin independent following treatment. One of the patients has been insulin-free for more than two years, while the other two have been free of the need for medication injections for six months and three months, respectively. At this point, the other three patients in the study have not had the device long enough to determine measurable results. The first three all have A1Cs in a normal, nondiabetic range. Sernova's Cell Pouch is an implantable device that releases the primary donor islets. The device is implanted under the skin in a minimally-invasive procedure. We're talking to Sernova for next week's show; long way to go here but another good result for stem cells. https://www.biospace.com/article/sernova-cell-pouch-device-keeps-type-1-diabetes-patient-insulin-free-for-two-years/ XX Getting closer to once-a-week basal insulin. New study says Novo Nordisk insulin icodec achieved better results than Lantus in some aspects of the study and that overall it was – this is interesting wording – non-inferior. Another previous study showed it also matched well to Tresiba, but that Tresiba caused fewer lows than the once-weekly basal. This study was about type 2 diabetes but insuln icodec is in other trials for people with type 1. https://www.biospace.com/article/novo-nordisk-scores-phase-iii-insulin-win-strengthening-market-position/ XX New partnership between Diabeloop – which makes an automated insulin algorithm - and SOOIL which makes pumps. These are two French companies that have been working together since 2020 but this new announcement was delayed by COVID. They want to bring the product – Diabeloop's DBLG-1 I controller and SOOIL's Dana ACE Pump to the US, Europe and Korea. https://www.drugdeliverybusiness.com/diabeloop-sooil-automated-insulin-diabetes/ XX Civica continues to move ahead with the development of its affordable insulins. They've announced they'll partner with the German company Profil for the clinical trials. Civica plans to set a maximum recommended price to the consumer of no more than $30 per vial and no more than $55 for a box of five pen cartridges. Contingent on FDA approval, Civica anticipates that its insulins will be available for purchase beginning in 2024. https://www.healthcarepackaging.com/supplier-news/news/22262909/civicarx-civica-selects-profil-as-clinical-trial-partner-for-affordable-insulin-initiative XX New study out of Israel shows that obesity in teenagers may lead to type 1 diabetes a few years later. The study, of nearly 1.5 million Israeli teenagers, found that those who were obese were twice as likely to develop type 1 diabetes by young adulthood, versus those in the normal weight range. The senior researcher on the study says it's not clear why obesity would raise the risk of type 1. They think it may the a trigger in people with genetically susceptible. Obesity also has other effects — including vitamin D deficiency and alterations in the gut's bacterial makeup — that could impair immune function. https://www.usnews.com/news/health-news/articles/2022-06-06/obesity-in-teen-years-might-trigger-type-1-diabetes XX Right back to the news in a moment but first we've got a new sponsor. As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX XX XX On this week's long format episode, you'll hear my conversation with Dexcom's CEO Kevin Sayer. We get more information about the G7 launch, after FDA approval of course and I asked him your questions about everything from IOS issues to airport scanners. Next week, Sernova joins me to explain their stem cell pouch technology Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.